Pfizer (PFE) Stock Forecast & Price Target

$27.69 +0.04 (+0.14%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$27.72 +0.03 (+0.11%)

As of 09/11/2026 07:59 PM Eastern

Compare

Pfizer - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 21 Analyst Ratings

Sell
2

Hold
14

Buy
5

Based on 21 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 2 have given a sell rating, 14 have given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for PFE.

Consensus Price Target

$28.39
2.52% Upside

According to the 21 analysts' twelve-month price targets for Pfizer, the average price target is $28.39. The highest price target for PFE is $35.00, while the lowest price target for PFE is $25.00. The average price target represents a forecasted upside of 2.52% from the current price of $27.69.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PFE Analyst Ratings Over Time

Type	Current Forecast 9/13/25 to 9/13/26	1 Month Ago 8/14/25 to 8/14/26	3 Months Ago 6/15/25 to 6/15/26	1 Year Ago 9/13/24 to 9/13/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	14 Hold rating(s)	14 Hold rating(s)	12 Hold rating(s)	11 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$28.39	$28.28	$28.82	$28.12
Forecasted Upside	2.52% Upside	5.62% Upside	10.82% Upside	17.60% Upside
Consensus Rating	Hold	Hold	Hold	Hold

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pfizer Stock vs. The Competition

Type	Pfizer	Healthcare Companies	Broader Market
Consensus Rating Score	2.19	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	2.52% Upside	891.32% Upside	16.41% Upside
News Sentiment Rating	Positive News See Recent PFE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/10/2026	HSBC 2 of 5 stars	Rajesh Kumar Not Rated	Boost Target	Hold	$28.00 ➝ $30.00	+7.82%
8/31/2026	Weiss Ratings 5 of 5 stars		Upgrade	Hold (C-) ➝ Hold (C)
8/7/2026	Guggenheim 5 of 5 stars	Vamil Divan 4 of 5 stars	Lower Target	Buy	$35.00 ➝ $31.00	+17.10%
7/13/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$34.00 ➝ $30.00	+23.89%
7/10/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Gerberry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$27.00 ➝ $26.00	+7.24%
7/8/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$30.00 ➝ $28.00	+15.44%
7/6/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$27.00	+11.15%
6/9/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Sector Perform	$25.00	-2.59%
5/27/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$27.00	+2.51%
5/14/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Underperform	$26.00	+0.17%
Get the Latest News and Ratings for PFE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.
4/29/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$26.00 ➝ $27.00	+2.10%
4/16/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jin Zhang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$33.00	+21.31%
4/10/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$27.00 ➝ $28.00	+3.65%
3/2/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$35.00	+26.78%
2/24/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
2/19/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Equal Weight ➝ Underweight	$25.00	-6.96%
2/12/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$27.00	-1.69%
12/30/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
11/13/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Sector Outperform	$30.00	+14.08%
11/5/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asad Haider Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$26.00	+7.06%
10/31/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Courtney Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform	$30.00	+22.88%
5/29/2025	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Hold	$28.00 ➝ $25.00	+6.66%
5/21/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$32.00 ➝ $33.00	+43.11%
4/30/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$29.00 ➝ $27.00	+10.61%
4/30/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Market Perform	$28.00 ➝ $26.00	+6.51%
12/18/2024	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$36.00 ➝ $32.00	+21.72%
10/30/2024	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:04 AM ET.

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, September 12, 2026. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

Here are some ways that investors could benefit from investing in Pfizer Inc.:

Pfizer Inc. offers a highly attractive dividend yield of 6.19%, which is significantly higher than the broader market average, providing a substantial income stream for investors who prioritize cash flow over capital appreciation.
The company recently demonstrated strong financial performance by beating consensus estimates in its most recent quarterly report, posting earnings per share of $0.77 against an expected $0.68 and generating revenue of $15.03 billion, which exceeded the $14.40 billion consensus estimate.
With a current stock price of $27.69, Pfizer Inc. trades at a valuation that is below the consensus analyst price target of $28.39, suggesting potential for modest upside as the stock remains near its 52-week high of $29.21.
The company maintains a low beta of 0.34, indicating that its stock price is significantly less volatile than the overall market, which can provide a stabilizing effect for conservative portfolios during periods of market uncertainty.
Pfizer Inc. is advancing its pipeline in high-growth therapeutic areas, including a Phase 3 trial for ritlecitinib in alopecia areata and new bets in obesity, which could drive future revenue growth beyond its current core portfolio.

Pfizer
Bear Case

Investors should be bearish about investing in Pfizer Inc. for these reasons:

The company has a dividend payout ratio of 226.32%, meaning it is paying out more than double its earnings in dividends, which raises concerns about the long-term sustainability of the dividend if earnings do not recover.
Pfizer Inc. carries a high price-to-earnings ratio of 36.43, which is elevated compared to many peers in the pharmaceutical sector, suggesting that the stock may be overvalued relative to its current earnings power.
Recent institutional activity shows mixed signals, with The Manufacturers Life Insurance Company reducing its holdings by 4.2% in the second quarter, indicating that some large investors are taking profits or reducing exposure to the stock.
The company faces a debt-to-equity ratio of 0.71, which, while manageable, represents a significant leverage level that could limit financial flexibility if interest rates remain high or if the company needs to invest heavily in new drug development.
Analyst sentiment remains cautious, with a consensus rating of "Hold" and a recent downgrade from Wall Street Zen from "buy" to "hold," reflecting uncertainty about the company's ability to sustain its recent earnings beats and growth trajectory.

PFE Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $28.39, with a high forecast of $35.00 and a low forecast of $25.00.

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 14 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.

According to analysts, Pfizer's stock has a predicted upside of 2.52% based on their 12-month stock forecasts.

Over the previous 90 days, Pfizer's stock had 2 downgrades and 1 upgrade by analysts.

Pfizer has been rated by research analysts at Bank of America, BMO Capital Markets, Cantor Fitzgerald, Guggenheim, HSBC, JPMorgan Chase & Co., and Weiss Ratings in the past 90 days.

Analysts like Pfizer less than other "healthcare" companies. The consensus rating score for Pfizer is 2.19 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how PFE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Pfizer Recommendations

MarketBeat monitors more than a dozen sources for Pfizer analyst ratings, with the most recent rating issued on 9/10/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Stock Forecast & Price Target

Pfizer - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

PFE Analyst Ratings Over Time

PFE Analyst Recommendations By Month

PFE Price Targets by Month

Pfizer Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

Pfizer
Bull Case

Pfizer
Bear Case

PFE Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Pfizer Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pfizer (PFE) Stock Forecast & Price Target

Pfizer - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

PFE Analyst Ratings Over Time

PFE Analyst Recommendations By Month

PFE Price Targets by Month

Pfizer Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

Pfizer Bull Case

Pfizer Bear Case

PFE Forecast - Frequently Asked Questions

What is Pfizer's forecast for 2026?

Should I buy or sell Pfizer stock right now?

Does Pfizer's stock price have much upside?

Has Pfizer been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Pfizer?

Do Wall Street analysts like Pfizer more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Pfizer Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Pfizer
Bull Case

Pfizer
Bear Case